Elevated Expression of Hypoxanthine Guanine Phosphoribosyltransferase within Malignant Tissue

M. Townsend, Abigail M. Felsted, Zachary E. Ence, Stephen R. Piccolo, R. Robison, K. O’Neill
{"title":"Elevated Expression of Hypoxanthine Guanine Phosphoribosyltransferase within Malignant Tissue","authors":"M. Townsend, Abigail M. Felsted, Zachary E. Ence, Stephen R. Piccolo, R. Robison, K. O’Neill","doi":"10.5539/CCO.V6N2P19","DOIUrl":null,"url":null,"abstract":"Hypoxanthine Guanine Phosphoribosyltransferase (HPRT) is a housekeeping enzyme involved in the purine synthesis of guanine and inosine in the salvage pathway. While other salvage pathway enzymes, such as TK1, have been established as biomarkers for both cancer cell proliferation and cancer development, little research been done to evaluate whether HPRT has the same potential as a cancer biomarker. We designed this study to determine if HPRT has value as an identifier of malignancy within the most common types of cancer. We utilized histological samples from lung, colon, prostate, and breast cancer with additional normal tissue to evaluate whether there was any elevation of HPRT within malignant samples. In addition, we also assessed general HPRT expression within patient’s samples from The Cancer Genome Atlas (TCGA) to confirm clinical relevance. We found that within a subset of patients, there was significant elevation of HPRT when compared to normal tissue controls. This elevation was seen in 33-55% of the malignant samples and appears to have no dependence on cancer stage. There were slight differences in staining patterns among all the organ types, but overall each organ displayed the same pattern of ‘HPRT high’ and ‘HPRT low’ populations within malignant samples. We found that in our TCGA samples, there was a similar elevation of HPRT that was significant when compared to normal controls. Overall, as an upregulated enzyme that does not directly correlate with stage, HPRT could become a valuable marker in the early diagnosis of a variety of solid tumors.","PeriodicalId":89904,"journal":{"name":"Cancer and clinical oncology","volume":"6 1","pages":"19"},"PeriodicalIF":0.0000,"publicationDate":"2017-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5539/CCO.V6N2P19","citationCount":"20","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer and clinical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5539/CCO.V6N2P19","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 20

Abstract

Hypoxanthine Guanine Phosphoribosyltransferase (HPRT) is a housekeeping enzyme involved in the purine synthesis of guanine and inosine in the salvage pathway. While other salvage pathway enzymes, such as TK1, have been established as biomarkers for both cancer cell proliferation and cancer development, little research been done to evaluate whether HPRT has the same potential as a cancer biomarker. We designed this study to determine if HPRT has value as an identifier of malignancy within the most common types of cancer. We utilized histological samples from lung, colon, prostate, and breast cancer with additional normal tissue to evaluate whether there was any elevation of HPRT within malignant samples. In addition, we also assessed general HPRT expression within patient’s samples from The Cancer Genome Atlas (TCGA) to confirm clinical relevance. We found that within a subset of patients, there was significant elevation of HPRT when compared to normal tissue controls. This elevation was seen in 33-55% of the malignant samples and appears to have no dependence on cancer stage. There were slight differences in staining patterns among all the organ types, but overall each organ displayed the same pattern of ‘HPRT high’ and ‘HPRT low’ populations within malignant samples. We found that in our TCGA samples, there was a similar elevation of HPRT that was significant when compared to normal controls. Overall, as an upregulated enzyme that does not directly correlate with stage, HPRT could become a valuable marker in the early diagnosis of a variety of solid tumors.
次黄嘌呤鸟嘌呤磷酸核糖基转移酶在恶性组织中的表达升高
次黄嘌呤鸟嘌呤磷酸核糖基转移酶(HPRT)是一种内务酶,参与鸟嘌呤和肌苷的嘌呤合成。虽然其他挽救途径酶,如TK1,已被确定为癌细胞增殖和癌症发展的生物标志物,但很少有研究评估HPRT是否具有作为癌症生物标志物的相同潜力。我们设计这项研究是为了确定HPRT在最常见的癌症类型中是否有作为恶性肿瘤标识符的价值。我们利用来自肺癌、结肠癌、前列腺癌和乳腺癌的组织学样本以及额外的正常组织来评估恶性样本中HPRT是否有升高。此外,我们还评估了来自癌症基因组图谱(TCGA)的患者样本中的一般HPRT表达,以确认其临床相关性。我们发现,在一部分患者中,与正常组织对照相比,HPRT显著升高。这种升高在33-55%的恶性样本中可见,似乎与癌症分期无关。所有器官类型的染色模式略有差异,但总体而言,每个器官在恶性样本中显示出相同的“HPRT高”和“HPRT低”群体模式。我们发现,在我们的TCGA样本中,与正常对照相比,HPRT有相似的显著升高。总之,作为一种与肿瘤分期不直接相关的上调酶,HPRT可能成为多种实体瘤早期诊断的有价值的标志物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书